The COVID19 pandemic has shown our health care fragility vis a vis novel pathogens, with a global disruption on societal welfare.Despite the towering success of vaccine development, lack of preparedness on integrative clinical and molecular phenotyping has emergedwith clarity and highlights the need to scale translational efforts for personalized prevention and therapy. Of particular concern are thelong-term consequences of SARS-CoV-2 infection with high and rising prevalence of chronic manifestations referred to as Post-COVID.Among these the neurological and psychiatric complications stand out for frequency, lack of treatment and devastating impact of theireffects at pandemic scale. Here, we tackle the cognitive and neurodegenerative complications of COVID-19, referred to as NeuroCOVID,as a ticking pandemic within the pandemic that requires an innovation leap across disciplines. We pursue a multi scalar approach thatreaches from epidemiology and mechanistic interrogation of host/virus interplay at single cell resolution through predictive modellingall the way to validation of biomarkers and repurposed drugs. The aim is to anticipate and effectively manage personalized trajectoriesof NeuroCOVID vulnerability and their impact at population level. For this we leverage two leading national health registries and threeclinical cohorts to characterize the phenotypic spectrum of NeuroCOVID, its risk factors and its socioeconomic burden at high definition.We pioneer innovative robotics to scale brain organoid modelling and combine it with single cell multiOMICs and AI analytics to dissectthe principles of the individual host response and render experimentally actionable the authentic genetic backgrounds of differentialSARS-CoV-2 sensitivity. Through a substantive engagement of patients’ collectives and health care stakeholders, upstream integrationof innovative pipelines streamlines translation and operationalizes precision medicine for emerging medical needs.